Hamdy A Azim
Overview
Explore the profile of Hamdy A Azim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
222
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Elghazaly H, Azim H, Rugo H, Cameron D, Swain S, Curigliano G, et al.
Cancer
. 2024 Jul;
130(19):3251-3271.
PMID: 38985794
Background: The management of early breast cancer (BC) has witnessed an uprise in the use of neoadjuvant therapy and a remarkable reshaping of the systemic therapy postneoadjuvant treatment in the...
2.
Azim H, Saleh M, Essam Eldin P, Abdelhafeez A, Hassan M, Kassem L
J Chemother
. 2024 May;
37(2):159-167.
PMID: 38764430
First line endocrine therapy is the gold standard for advanced estrogen receptor positive, human epidermal growth factor receptor 2 negative breast cancer. Adding CDK4/6 inhibitors has improved progression free survival....
3.
Aboelhassan R, Sobeih M, El-Din M, Ghali R, El-Din I, Khorshid O, et al.
Ther Adv Med Oncol
. 2023 Nov;
15:17588359231212182.
PMID: 38028146
Background: Stage III non-small cell lung cancer (NSCLC) being highly heterogeneous requires multimodal therapeutic strategies for optimal management. We present findings on treatment patterns and their associated survival outcomes in...
4.
Azim H, Loutfy S, Azim Jr H, Kamal N, Abdel Fattah N, Elberry M, et al.
Oncol Ther
. 2023 Sep;
11(4):445-459.
PMID: 37731153
Background: Deleterious germline mutations in BRCA1 and BRCA2 genes are associated with a high risk of breast and ovarian cancer. In many developing countries, including Egypt, the prevalence of BRCA1/2...
5.
Azim H, Elghazawy H, Ghazy R, Abdelaziz A, Abdelsalam M, Elzorkany A, et al.
JCO Glob Oncol
. 2023 Mar;
9:e2200387.
PMID: 36888929
Purpose: Breast cancer (BC) is the most common cancer among Egyptian females. No current national cancer database is available in Egypt to provide reliable data on the specific clinicopathologic features...
6.
Azim H, Shohdy K, Elghazawy H, Salib M, Almeldin D, Kassem L
Biomarkers
. 2022 Aug;
27(8):764-772.
PMID: 35980714
Background: In patients with metastatic triple-negative breast cancer (TNBC), programmed death-ligand 1 (PD-L1) expression has been demonstrated to predict response to immunotherapy. It is unclear whether PD-L1 expression measured with...
7.
De Laurentiis M, Borstnar S, Campone M, Warner E, Salvador Bofill J, Jacot W, et al.
Breast Cancer Res Treat
. 2021 Oct;
191(1):223-224.
PMID: 34625861
No abstract available.
8.
De Laurentiis M, Borstnar S, Campone M, Warner E, Salvador Bofill J, Jacot W, et al.
Breast Cancer Res Treat
. 2021 Aug;
189(3):689-699.
PMID: 34414532
Purpose: CompLEEment-1 is a phase 3b trial in an expanded patient population with hormone receptor-positive (HR +), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC), the largest current...
9.
Elghazaly H, Rugo H, Azim H, Swain S, Arun B, Aapro M, et al.
Cancers (Basel)
. 2021 Jun;
13(9).
PMID: 34066769
: The management of patients with triple-negative breast cancer (TNBC) is challenging with several controversies and unmet needs. During the 12th Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egypt, 2020,...
10.
Azim H, Kassem L, Azim Jr H
Chin Clin Oncol
. 2021 Jan;
10(5):50.
PMID: 33440946
During the last 2 decades, extensive research has focused on the molecular functions of BRCA1 and BRCA2 genes. This has led to the development of Poly(ADP-ribose) polymerase inhibitors (PARPi), as...